Breakthrough radiotherapy for pancreatic cancer

Providence Cancer Institute is the first facility in the Pacific Northwest, and the first community medical center in the country, to offer MRI-guided radiation therapy for patients with pancreatic cancer and other malignancies. 

This breakthrough treatment is delivered by state-of-the-art MR-Linac technology, which provides real-time visualization of the treatment field. With pin-point accuracy, radiation oncologists can monitor changes in the shape of the target and surrounding organs during treatments to maximize tumor killing and minimize damage to normal tissue. A new phase II study will evaluate clinical outcomes of patients receiving MR-Linac therapy for pancreatic cancer:

Stereotactic Magnetic Resonance Imaging (MRI) Guided On-table Adaptive Radiation Therapy (SMART) for Patients with Borderline or Inoperable Locally Advanced Pancreatic Cancer

In this prospective study, known as SMART, patients will receive MRI-guided stereotactic radiation therapy (SBRT) with on-table adaptive re-planning when clinically indicated. Investigators will assess grade 3 or greater GI toxicity and median overall survival compared to patients who receive more conventional radiation doses without frequent dose adaptation. A prior study of MRI-guided SBRT with adaptive re-planning showed clinical benefit in patients with pancreatic cancer.

The study is led by Kristina Young, M.D., Ph.D., a Providence radiation oncologist and assistant member at the Earle A. Chiles Research Institute where she leads the Tumor Microenvironment Laboratory. Dr. Young’s lab investigates radiation effects on the tumor microenvironment and how to enhance the local and systemic effects of radiotherapy.

In a companion study to the SMART trial, Dr. Young leads an investigator-initiated correlative trial, called Tracking Outcomes and Toxicity of Patients Treated on the MR-Linac, to evaluate whether MRI-derived biomarkers correlate with local cancer control.

The researchers hypothesize that patients treated on the MR Linac will receive higher doses of radiation to the tumor, lower doses to adjacent critical structures, have improved local control, and reduced toxicity. Any patient who receives treatment on the MR Linac is eligible to participate in this study.

For more information about these featured studies at Providence Cancer Institute, or to enroll a patient, submit a referral form or call our Clinical Research office at 503-215-2614.

See more studies for patients with pancreatic cancer

Providence Cancer Institute currently has 10 studies open for patients with pancreatic cancer, and nearly 150 studies open for all cancer types.

A team approach for comprehensive care

Providence Cancer Institute is home to the Elsie Franz Finley Radiation Oncology Center and Providence Hepatobiliary and Pancreatic Cancer Program.  Together, these programs serve as a "single-source" center where patients with liver and pancreas disease receive a comprehensive approach to cancer care with a wide range of world-class cancer therapy modalities. 

Our multidisciplinary team of experts, coupled with leading-edge technology, creates the environment for superior treatment outcomes for cancer patients. Our physicians and staff are dedicated to delivering compassionate care for our patients while offering support to their families. Patient-centered care is our philosophy at Providence Cancer Institute.

Previous Article
Providence Continues to Invest in Southwest Washington’s Health
Providence Continues to Invest in Southwest Washington’s Health

Next Article
Watch video: Journeys in bariatric surgery - Ingga’s story
Watch video: Journeys in bariatric surgery - Ingga’s story

Ingga Smith describes her life before and after having bariatric surgery at the Providence Little Company o...